Fortis Healthcare Q3 Results: Net Profit Soars 83% YoY

Fortis Healthcare in Focus After Reporting 83% YoY Increase in Net Profits

Fortis Healthcare, a leading mid-cap healthcare company with a hospital and diagnostics chain, is gaining attention after reporting its Q3 results, which showcased robust net profit growth and positive performance in both its hospital and diagnostics segments.

Stock Performance

With a market capitalization of Rs. 47,298 Crore, Fortis Healthcare opened at Rs. 662, up 1.89 percent from the previous day's close, also marking the intraday high. The stock has seen a -9 percent return in the past month and an impressive 302 percent return over the past five years.

Q3FY25 Financial Results

• Revenue: Increased by 14.79 percent YoY, from Rs. 1679.68 Crore in Q3FY24 to Rs. 1928.26 Crore in Q3FY25. However, there was a 3.02 percent QoQ decrease from Rs. 1988.39 Crore in the previous quarter.
• Net Profit: Surged by 82.74 percent YoY, from Rs. 134.23 Crore to Rs. 254.30 Crore. On a QoQ basis, net profits also increased by 37.70 percent from Rs. 193.08 Crore.
• Operating Profit Margin: Stood at 19.62 percent for Q3FY25 compared to 17.20 percent for Q3FY24.
• Net Profit Margin: Reached 11.99 percent, up from 7.54 percent in the same period last year.

Segment Analysis

The company's revenue is primarily derived from two key segments:

• Healthcare Segment: Accounts for 82.58 percent of total revenue.
• Diagnostics Segment: Contributes the remaining 17.42 percent.

Operational Highlights

Hospital Business

• Occupancy Rate: Increased to 67 percent for Q3 FY25, up from 64 percent in Q3 FY24.
• Average Revenue Per Bed: Increased to Rs. 2.45 Crore/annum, compared to Rs. 2.23 Crore in the same period last year.
• Average Length of Stay: Slightly decreased to 4.20 Days, compared to 4.32 Days.

The company continued its portfolio rationalization strategy by divesting the business operations of the Richmond Road facility in Bangalore. This is the third divestment, following the Malar facility (Feb’24) and the Vadapalani facility (Jul’23) in Chennai.

Diagnostics Business

• Operating EBITDA Margin: Increased to 14.4 percent, up from 10 percent in Q3 FY24.
• Total Tests Conducted: Reached 10.29 Million, compared to 9.85 Million in the same period.

Fortis Healthcare consolidated its stake in Agilus Diagnostics Limited from 57.68 percent to 89.20 percent, utilizing funds from the Rs 1,550 Crore raised through NCDs.

About Fortis Healthcare

Fortis Healthcare Limited, an IHH Healthcare Berhad Company, is a leading integrated healthcare services provider in India. With 27 healthcare facilities, over 4,700 operational beds, and over 405 diagnostics centers, Fortis has a significant presence in India, the United Arab Emirates (UAE), Nepal, and Sri Lanka.

Disclaimer: The views and investment tips expressed in this article are for informational purposes only and do not represent financial advice. The views expressed are those of the sources cited and not necessarily those of this website or its management. Investing in equities or other financial instruments carries the risk of financial loss. Readers must exercise due caution and conduct their own research before making any investment decisions. We are not liable for any losses incurred as a result of decisions made based on this article. Please consult a qualified financial advisor before making any investment.

Categories: Fortis Healthcare, Q3 Results, Stock Market News